Gastroenterology
Fibrostenotic Crohn's Disease
3
Pipeline Programs↗
3
Active Trials↗
1
Companies Involved↗
Fibrostenotic Crohn's Disease is an early-stage landscape with 3 programs across 1 company. The most active players are Eli Lilly.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical
No programs
Phase 3
No programs
Approved
No programs
Analysis
Trial Status
4
clinical trials
Not yet recruiting3 · 75%
Completed1 · 25%
Clinical Trials
Trial Activity
Risankizumab for Fibrostenotic Crohn's Disease Treatment
Not yet recruiting·FFirst Affiliated Hospital of Wenzhou Medical University·Phase 3·NCT07177118·260 enrolled
A Phase 2b, Randomized, Placebo-controlled, Double-blind, Dose-ranging Trial to Assess the Efficacy and Safety of Ontunisertib in Patients With Fibrostenosing Crohn's Disease
Not yet recruiting·—·Phase 2·NCT07683325·320 enrolled
An Open-label, Two-part Trial to Assess the Mass-balance Recovery, Metabolite Profile, Metabolite Identification and Absolute Bioavailability of [14C] Ontunisertib in Healthy Male Participants
Not yet recruiting·—·Phase 1·NCT07672574·8 enrolled
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)